The WIDER PVI study is a multicentre randomized clinical trial to compare the efficacy of antral versus extended antral PVI in patients with paroxysmal or persistent AF undergoing this procedure using a cryoablation balloon capable of 28 mm diameter (antral isolation) or 31 mm diameter (extended antral isolation) applications. The aim is to evaluate an objective of superiority of the extended antral isolation strategy versus antral isolation in the recurrence of atrial tachyarrhythmias at 1-year follow-up, both in episodes of \>30 seconds duration and in overall arrhythmic load.
Ablation has become a first-line therapy in the rhythm control strategy for atrial fibrillation (AF). Pulmonary vein electrical isolation (PVI) is the cornerstone of ablation therapy, based on its efficacy profile, safety and lack of alternatives. Single shot techniques have been increasingly used as the initial approach for PVI, employing cryoablation, i.e. release of cryoenergy into the endocardium via an inflatable catheter, to achieve isolation. The most commonly used diameter in cryoablation is 28 mm. These generate antral isolation whose profile depends on the distance between veins. When the application is made with larger devices, as has been observed with the cryoballoon with an expandable diameter of 31 mm or ablation devices using pulsed electric fields, the isolation is also antral at the level of the carina, making the result of PVI more similar to that obtained when ablation is performed with a Wide Antral Circumferential Ablation (WACA) strategy using point-to-point radiofrequency (the gold standard for PVI). The WIDER-PVI study aims to answer the question of whether single-shot ablation with a 31 mm diameter device is superior to conventional ablation with a 28 mm diameter device. The answer to this question is relevant in the context of the development of new, larger devices and concerns about the impact of larger ablation on atrial function.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
440
Pulmonary vein isolation using 28 mm balloon cryoablation
Pulmonary vein isolation using 31 mm balloon cryoablation
IRCCS Neuromed Mediterranean Neurological Institute
Pozzilli, Isernia, Italy
NOT_YET_RECRUITINGCasa di cura Villa dei Fiori
Acerra, Napoli, Italy
NOT_YET_RECRUITINGPoliambulanza Institute Hospital Foundation
Brescia, Italy
NOT_YET_RECRUITINGOspedale Santa Maria Goretti
Latina, Italy
NOT_YET_RECRUITINGClinica San Michele
Maddaloni, Italy
NOT_YET_RECRUITINGFondazione IRCCS San Gerardo dei Tintori
Monza, Italy
NOT_YET_RECRUITINGPellegrini Hospital
Napoli, Italy
NOT_YET_RECRUITINGDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova
Padua, Italy
NOT_YET_RECRUITINGFondazione Policlinico Universitario Agostino Gemelli IRCCS, University "Cattolica del Sacro Cuore"
Rome, Italy
NOT_YET_RECRUITINGS. Pietro Fatebenefratelli Hospital
Rome, Italy
NOT_YET_RECRUITING...and 7 more locations
Recurrence of atrial tachyarrhythmia
Presence of atrial fibrillation, atrial flutter, atrial tachycardia in which the atrial rate exceeds 180 beats per minute, lasting more than 30 seconds after the blanking period (8 weeks) and without pharmacological anti-arrhythmic treatment during 12 months of follow-up with continuous ECG monitoring (in patients with continuous implantable monitor) or combined (in patients without implantable monitor), by optical heart rate monitoring combined with programmed intermittent ECG and in response to detection of heart rate irregularity).
Time frame: From enrollment to the end of follow up, assessed up to 12 months
Arrhythmic load
Percentage of time the patient has atrial tachyarrhythmia (atrial fibrillation, atrial flutter, atrial tachycardia in which the atrial rate exceeds 180 beats per minute) over the total monitored time.
Time frame: From enrollment to the end of follow up, assessed up to 12 months
Arrhythmic load
Total duration of the longest episode of atrial tachyarrhythmia for each patient (cut off point: 60 minutes)
Time frame: From 0 up to 60 minutes for every atrial tacharrhythmia detected in each patient
Acute effectiveness
* Percentage of veins in which complete occlusion (grade 4) is achieved pre-application * Percentage of veins requiring change to other than randomly assigned diameter * Percentage of patients in whom time to electrical isolation is visualised * Percentage of patients in whom pulmonary vein isolation is achieved at first application * Percentage of patients with termination of AF during applications, transitioning to sinus rhythm or to atrial tachycardia or flutter
Time frame: Every measure is assessed through procedure time, an average of 180 minutes
Effectiveness in follow-up
* Cardiovascular admissions * Visit to the emergency room for cardiovascular conditions * Death from any cause / death from cardiovascular cause * stroke/transient ischaemic attack * Percentage of patients requiring electrical or pharmacological cardioversion or new ablation for atrial tachyarrhythmia. * Percentage of patients with recurrence of AF after the blanking period and without pharmacological antiarrhythmic treatment. * Time to first recurrence of atrial tachyarrhythmia * Improvement in Atrial Fibrillation Effect on Quality of Life Questionnaire (AFEQT) score from visit 0 (pre-ablation) to follow-up visit 12 months after ablation.
Time frame: Until the end of the study
Safety
* Major (death, complication requiring surgical or interventional treatment (vascular, coronary, cardiac, others) or prolongation of hospital stay \>48 hours, or complication with chronic sequelae or requiring chronic treatment for its management) and minor adverse events * Intra-procedural complication rate
Time frame: Until the end of the study
Acute effectiveness
* Total procedure duration * Left atrial dwell time * Radiation exposure (fluoroscopy time and dose-area product) * Time to pulmonary vein electrical isolation
Time frame: Every measure is assessed through procedure time, an average of 180 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.